Groundbreaking Early Cancer Detection Test Studied at Mayo Clinic Introduced Nationally

Date :
Mayo Clinic today recognized the debut of a groundbreaking multi-cancer early cancer detection (MCED) test called Galleri™ that can detect more than 50 types of cancers[1] through a simple blood draw. The Galleri test is intended to complement U.S. guideline-recommended cancer screenings.

Mayo Clinic Oncologist Minetta Liu, M.D. was involved in the development of the new test.

“Today, many cancers are found too late, leading to poor outcomes,” says Dr. Liu. “The ability to detect cancer early is critical to successful treatment.”

Cancer is expected to become the leading cause of death in the U.S. this year. Currently recommended cancer screening tests only cover five cancer types and screen for a single cancer at a time. In fact, there are no recommended early detection screening tests for other cancers, which account for 71% of cancer deaths.

Researchers used the Galleri test in the Circulating Cell-free Genome Atlas (CCGA) Study, a prospective, observational, longitudinal study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. In the study, the Galleri test demonstrated the ability to detect more than 50 types of cancers — over 45 of which have no recommended screening tests today — with a low false-positive rate of less than 1%.

According to Dr. Liu, when a cancer signal is detected, the Galleri test can identify where in the body the cancer is located with high accuracy — a critical component to help enable health care providers to direct diagnostic next steps and care.

Combining for a Cure

Date :
Valerie Lee is investigating a new treat­ment approach that may make currently incurable pancreatic cancers curable.

Hope For the Most Advanced Pancreatic Cancers

Date :
The Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care attracts the most accomplished young investigators interested in pursuing a career in pancreatic cancer research and treatment. By training with established investigators, Skip Viragh Center fellows are helping advance the science and bringing much-needed new therapies to patients.

Innovative Pancreatic Cancer Treatment Saves Nancy's Life

Date :
Innovative Pancreatic Cancer Treatment Saves Nancy's Life
Nancy Amato had surgery to remove a tumor in her pancreas, then began an innovative program developed at the Skip Viragh Center for Pancreatic Cancer at Johns Hopkins to activate her immune system to prevent the cancer from recurring.

Ludwig Johns Hopkins researchers devise new strategy for cancer immunotherapy

Date :
MARCH 1, 2021, NEW YORK – Researchers at the Ludwig Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed a new strategy for immunotherapy that targets specific genetic alterations commonly associated with cancer to generate a therapeutic immune response. Evaluated in preclinical studies, the strategy employs an antibody technology to target commonly seen alterations in the p53 tumor suppressor gene and cancer-driving RAS gene to stimulate an immune attack on tumors. The studies behind the development of the strategy, led by Ludwig Johns Hopkins investigator Shibin Zhou, its Co-director Bert Vogelstein and their Johns Hopkins colleagues Suman Paul and Sandra Gabelli, are reported in three papers in the current issues of Science Immunology, Science, and Science Translational Medicine.

Pan-Cancer Project

Date :
What is the Pan-Cancer project?
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes project, known as the Pan-Cancer project, is an international collaboration with the aim of identifying common patterns of mutation in more than 2600 whole cancer genomes from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). It builds upon the previous work of those initiatives, which focused primarily on the regions of the genome that code for proteins.

Pan-Cancer Analysis of Whole Genomes

Date :
Cancer is a disease of the genome, caused by a cell's acquisition of somatic mutations in key cancer genes. These mutations alter pathways involved in regulating cellular growth and interactions with the tissue environment. Until recently, research on the cancer genom

The Contagion Year What we learned about treating COVID-19 in Year One of the pandemic

Date :
This article is part of Harvard Medical School’s continuing coverage of medicine, biomedical research, medical education, and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.

The emergence of SARS-CoV-2 in December of 2019 in China, the microbe ripping across the globe, its uncontrolled spread in the United States …

This dizzying cascade of events overwhelmed hospitals and forced physicians in the trenches to figure out on the fly how to treat a mystifying disease caused by a new virus.

Demandez dès maintenant une prise en charge

Votre message a bien été envoyé

Ribau & Garner
121 avenue des Champs Elysées
75008 - Paris
Accueil téléphonique :

du lundi au jeudi de 9h à 19h
et le vendredi jusqu'à 18h

+ 33 (0) 1 72 71 85 46
Accueil WhatsApp : 24h/24, 7j/7
+ 33 (0) 6 88 37 49 65
Mail :

Nous soutenons une économie responsable